The last decade has seen significant growth in the pre- and clinical development of synthetic immunotherapies of cancer using bi-/multi-specific immune cell engaging molecules. This meeting will focus on the latest developments in the field, on emerging biological understanding of the mechanism of action of immune cell engagers and of mechanisms of primary and secondary resistance. Researchers from academia and industry will cover novel technologies and approaches to enhance safety, efficacy and tumor specificity, including addressing resistance, adding synergistic immune cell agonism, engaging alternative immune cells, novel molecular formats, conditional tumor activation and generation of adaptive responses.